PDE5 inhibitors for pulmonary hypertension
PDE5 inhibitors are medicines that block phosphodiesterase type 5, an enzyme that breaks down a signalling molecule called cGMP. The US labels of Revatio (sildenafil) and Adcirca (tadalafil) each call the product a PDE5 inhibitor indicated for the treatment of pulmonary arterial hypertension. Both labels describe the medicine as raising cGMP in the smooth muscle cells of the blood vessels of the lungs, which relaxes them. This class page covers the use for pulmonary arterial hypertension only; the same ingredients have other labels that are not covered here.
Also called Phosphodiesterase 5 Inhibitor · Phosphodiesterase 5 Inhibitors · PDE5 inhibitors · PDE-5 inhibitors · Phosphodiesterase Type 5 Inhibitors
- Drug
- In this atlas
Overview
Technical summary
Class page, scoped to the pulmonary arterial hypertension labels of the medicines. MeSH descriptor D058986 (Phosphodiesterase 5 Inhibitors, lastUpdated 2020-05-27) is a broad match: its scope note says the compounds specifically inhibit phosphodiesterase 5, and the descriptor is not limited to pulmonary hypertension. RxClass lists the established pharmacologic class on US drug labels Phosphodiesterase 5 Inhibitor for sildenafil and for tadalafil (read 2026-11-18). The labels read are Revatio (NDA203109, NDA022473, NDA021845; effective 2024-12-18) and Adcirca (NDA022332; effective 2025-12-15). Labels of the same ingredients for other uses were not read. No trial result, dose or instruction is recorded.
Drugs in this class
2 drugs in this atlas are filed under PDE5 inhibitors for pulmonary hypertension, with the registry trials and FDA regulatory decisions this atlas holds for each. With PDE5 inhibitors for pulmonary hypertension itself, the class has 0 distinct trials and 0 distinct FDA decisions; a trial or decision that two of them share counts once there.
About this drug
- Level
- Class
- Mechanism
- The Adcirca label says tadalafil is an inhibitor of phosphodiesterase type 5, the enzyme responsible for the degradation of cGMP; the Revatio label says sildenafil inhibits cGMP specific PDE-5 in the smooth muscle of the pulmonary vasculature.
Classification codes
-
D058986Phosphodiesterase 5 Inhibitors
Claims and evidence
No claims are published for this drug yet.
Record details
- Record id
cardio:pde5-inhibitors-for-pulmonary-hypertension- Content hash
bf8ea453ea8d5a3210c066b2733c9dafc01d75c5297568ec3a7cb38df6aaa1b4